These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36645458)

  • 21. Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma.
    Oyake T; Maeta T; Takahata T; Tamai Y; Kameoka Y; Takahashi N; Miyairi Y; Murai K; Shimosegawa K; Yoshida K; Inokura K; Fukuhara N; Harigae H; Sato R; Ishizawa K; Tajima K; Saitou S; Fukatsu M; Ikezoe T; Tsunoda S; Mita M; Mori J; Kowata S; Ito S
    J Clin Exp Hematop; 2024 Sep; 64(3):191-202. PubMed ID: 39085129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
    Le-Nguyen A; Rys RN; Petrogiannis-Haliotis T; Johnson NA
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1432. PubMed ID: 34047076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
    Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
    Epperla N; Hamadani M
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):247-253. PubMed ID: 34889401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
    Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
    Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
    J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
    Yu W; Geng M; Hao J; Yan Z; Mi JQ
    Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
    Greve P; Beishuizen A; Hagleitner M; Loeffen J; Veening M; Boes M; Peperzak V; Diez C; Meyer-Wentrup F
    Front Immunol; 2023; 14():1229558. PubMed ID: 37583696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
    Özbalak M; Salihoğlu A; Soysal T; Karadoğan İ; Paydaş S; Özdemir E; Yıldız B; Karadurmuş N; Kaynar L; Yagci M; Özkocaman V; Topçuoğlu P; Özcan M; Birtaş E; Göker H; Ferhanoglu B
    Ann Hematol; 2020 Feb; 99(2):301-307. PubMed ID: 31844933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma.
    Lorente Fernández L; Romero Domínguez S; Albert Marí A; Núñez Benito E; López Briz E; Poveda Andrés JL
    Farm Hosp; 2024 Jun; ():. PubMed ID: 38839541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
    Hanel W; Shindiapina P; Bond DA; Sawalha Y; Epperla N; Voorhees T; Welkie RL; Huang Y; Behbehani GK; Zhang X; McLaughlin E; Chan WK; Brammer JE; Jaglowski S; Reneau JC; Christian BA; William BM; Cohen JB; Baiocchi RA; Maddocks K; Blum KA; Alinari L
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
    Manji F; Laister RC; Kuruvilla J
    Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.